argenx Drug Pipeline

argenx maintains a substantial clinical portfolio, with 26 active trials out of 66 total registered since 2008. Clinical activity spans early- and late-stage development, with two active Phase 1, 14 Phase 2, and 14 Phase 3 trials, plus one Phase 4 trial. The portfolio covers five therapeutic areas, but is most heavily weighted toward Rare Diseases, which accounts for 15% of active programs. Within Rare Diseases, the leading indications are Immune Thrombocytopenia, with three active trials all in Phase 3, and Spinal Muscular Atrophy, with one active trial in Phase 2. Central Nervous System indications represent the next-largest concentration, with three active trials. The late-stage weighting of the portfolio, with a high proportion of programs in Phase 3, suggests a focus on near-term clinical catalysts.